Top-News

Zenas BioPharma Aktie News

Aktie
WKN:  A40MUX ISIN:  US98937L1052 US-Symbol:  ZBIO Branche:  Biotechnologie Land:  USA
39,38 $
+1,27 $
+3,33%
33,797 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
1,27 Mrd. €
Streubesitz
-
KGV
-2,18
Index-Zuordnung
-

Zenas BioPharma News

05.05.25 - PR Newswire
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
02.05.25 - PR Newswire
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO PR Newswire
01.05.25 - PR Newswire
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
29.04.25 - PR Newswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm PR Newswire
29.04.25 - PR Newswire
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO PR Newswire
28.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO PR ...
28.04.25 - PR Newswire
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action ...
28.04.25 - PR Newswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
28.04.25 - PR Newswire
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO PR Newswire
25.04.25 - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc.(ZBIO) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc.(ZBIO) Shareholders PR Newswire
24.04.25 - PR Newswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm PR Newswire
24.04.25 - PR Newswire
The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ZBIO
The Gross Law Firm Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ZBIO PR Newswire
22.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO PR ...
22.04.25 - PR Newswire
Contact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc.(ZBIO)
Contact Levi & Korsinsky by June 16, 2025 Deadline to Join Class Action Against Zenas BioPharma, Inc.(ZBIO) PR Newswire
21.04.25 - PR Newswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
21.04.25 - PR Newswire
ZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PR Newswire
21.04.25 - PR Newswire
Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO PR Newswire
20.04.25 - PR Newswire
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action ...
19.04.25 - PR Newswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm PR Newswire
18.04.25 - PR Newswire
Shareholder Alert: Robbins LLP Informs Stockholders of the Zenas BioPharma, Inc. Class Action Lawsuit
Shareholder Alert: Robbins LLP Informs Stockholders of the Zenas BioPharma, Inc. Class Action Lawsuit PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,14%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »